Digitate Accelerates Momentum as an Industry Leader in the AIOps Market
Digitate, a SaaS-based, leading provider of autonomous enterprise solutions, today announced its recognition as a market and category leader in AIOps by multiple leading analyst firms and industry reports. Digitate earned these merits as a result of its high customer ratings and wide breadth of solutions that span across IT and business operations, as well as assurance.
Digitate’s flagship product ignio™ is an end-to-end autonomous solution that uses advanced machine learning and AI capabilities to bring contextual intelligence to IT operations. ignio™ enables enterprises with a one-of-a-kind closed-loop solution that combines context, insights and intelligent automation to autonomously predict, prevent and prescribe for issues. Digitate is helping Fortune 500 companies harness the power of AI and automation as they scale to meet the demands of their own customers and ease the ever-increasing workload on IT teams.
"Our growth over the past few years speaks to the strength of our solutions in supporting our customers' goals for digital transformation success,” said Akhilesh Tripathi, CEO of Digitate. “Digitate is committed to providing customers an AI-driven, closed-loop platform that further improves productivity, business continuity, and customer experience. Our recognition as a market leader by several prominent analyst and industry reports is a validation of our investments and the adoption of our solutions across some of the world’s leading enterprises”
Digitate’s success is highlighted by several notable achievements and recognition in 2021, including:
- Named a leader in the Omdia “AIOps Universe – Selecting an AIOps Solution 2021 - 2022” Report – Due in part to its strong automation capabilities and management control, Digitate was recognized for its commitment to creating value for business functions through automation and comprehensive AIOps capabilities. Digitate was the leader in the overall customer experience with a recommendation score of 96%. To support Digitate’s all-rounder status, it scored 95% for solution breadth.
- Recognized on the Constellation Research ShortList™ for Using Artificial Intelligence in IT Operations (AIOps) Q3 2021 – Constellation’s list evaluated over 40 most prominent AIOps solutions based on client inquiries, partner conversations, customer references, vendor selection projects, market share and internal research. Digitate was selected based on its noise reduction and enterprise capabilities, among other criteria.
- Recognized as a technology leader in Quadrant Knowledge Solution’s SPARKS Matrix for Artificial Intelligence for IT Operations (AIOps) Platform 2021 Report –The report pointed out some of the key differentiators that include Digitate’s over 10 000 out-of-the-box automation capabilities and unique, closed-loop system ensuring better ROI and lower time to value.
- Highlighted in the IDC Worldwide IT Operations Analytics Software Market Shares Report – Digitate was the second fastest-growing IT Operations Analytics software company for 2020, with a revenue growth rate of 43.5%. (August 2021, IDC #US48125121)
- Highlighted in the IDC Worldwide Workload Management Software Market Shares Report – Digitate was the fastest growing WLM software company for 2020 with a revenue growth rate of 75.6 %. (July 2021, IDC #US48063321)
About Digitate
Digitate is a leading software provider bringing agility, assurance, and resiliency to IT and business operations. Digitate’s flagship product ignio™ is an award-winning AIOps software that reimagines enterprise IT and business landscape with its unique and innovative closed-loop approach by combining context, insights and intelligent automation to autonomously resolve and prevent issues. Our customers span across industry verticals and include large, global enterprises that are leaders and innovators in their respective industries. Digitate is headquartered in Santa Clara, California, USA and Pune, India. To stay up to date on ignio™ news and to learn more how our clients across the globe have benefited from our innovative solutions: Visit us at www.digitate.com, and follow Digitate on Twitter and LinkedIn.
Learn more about our AIOps solution here: http://www.youtube.com/watch?v=xy3FGkbZNDM
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005225/en/
Contact information
Colin Rinehart
Senior Account Executive
10Fold/Digitate
digitate@10fold.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom